If you live with diabetes, you may have heard your doctor mention neuropathy — but what does it actually mean for your feet, and why does catching it early matter so much? Diabetic peripheral neuropathy (DPN) is one of the most common and serious complications of both Type 1 and Type 2 diabetes, affecting up to 50% of people with the condition over their lifetime. The encouraging news is that advances in screening tools and a new generation of treatments are giving patients and clinicians better options than ever before.
What Is Diabetic Peripheral Neuropathy?
Diabetic peripheral neuropathy is nerve damage caused by prolonged exposure to high blood glucose levels. It most commonly affects the feet and lower legs — producing symptoms that range from tingling, burning, and stabbing pain to complete numbness. When feeling is lost, small injuries like blisters or cuts can go unnoticed and quickly escalate into serious wounds, infections, or even limb-threatening ulcers.
What makes DPN particularly challenging is that by the time most people notice symptoms, significant nerve damage has already occurred. This is why routine screening — before problems arise — is so important.
When and How Should Screening Happen?
The American Diabetes Association’s 2024 Standards of Care recommend that all patients with Type 2 diabetes be screened for DPN at the time of diagnosis, and that those with Type 1 diabetes begin screening five years after their diagnosis. After that, annual screening is recommended for everyone with diabetes.
A comprehensive screening exam is straightforward and non-invasive. It typically includes:
- Monofilament testing — a thin filament is pressed against specific points on the foot to assess pressure sensation
- Tuning fork or biothesiometer testing — measures vibration sense, one of the earliest nerve functions to decline
- Ankle reflex assessment and a thorough review of foot skin integrity, temperature, and circulation
These simple, in-office tools can detect neuropathy long before it causes serious complications — which is exactly when intervention is most effective. No single test is a gold standard, which is why a multidisciplinary approach to screening and care is strongly recommended in current clinical guidelines (Frontiers in Endocrinology, 2024).
Managing Painful Diabetic Neuropathy: From Standard Treatments to Breakthrough Therapies
For patients who experience painful DPN, the goal of treatment is threefold: address the underlying cause (primarily through better blood glucose control and lifestyle changes), target the nerve damage mechanisms, and relieve pain to restore quality of life.
First-Line Medications
Most international guidelines — including those from the ADA and the European Federation of Neurological Societies — recommend four medications as first-line options for painful DPN:
- Duloxetine (SNRI antidepressant with proven analgesic effects)
- Pregabalin and gabapentin (anticonvulsants that calm overactive pain nerves)
- Amitriptyline (a tricyclic antidepressant used at low doses for neuropathic pain)
While these medications help many patients, studies show that traditional pharmacotherapy provides meaningful relief for only 30–50% of people with painful DPN, and side effects lead many patients to stop treatment within the first year. This has driven the development of newer, device-based approaches.
Emerging Device-Based Treatments
Several innovative neuromodulation therapies have received FDA approval in recent years, offering new hope for patients whose pain is not adequately controlled by medications:
Spinal Cord Stimulation (SCS): Five SCS systems received FDA approval for painful DPN between 2021 and 2023. The landmark SENZA-PDN trial demonstrated that after 24 months, approximately 90% of patients using high-frequency SCS achieved 50% or greater reduction in pain scores — compared to just 5% of patients on conventional medical management alone. These are remarkable results for a condition that has historically been very difficult to treat.
Magnetic Peripheral Nerve Stimulation (mPNS): In 2024, the FDA cleared a new non-invasive treatment called Axon Therapy (by Neuralace Medical) for painful DPN. This technology uses magnetic pulses delivered in 13-minute sessions to activate pain-relief pathways in peripheral nerves. In clinical trials, 71% of patients receiving mPNS plus conventional therapy achieved greater than 50% pain relief at three months, compared to only 13% in the conventional-therapy-only group — a striking difference that points to the power of targeting nerve function directly.
The Role of Lifestyle and Blood Sugar Control
No medication or device can fully substitute for optimizing blood glucose management. Sustained high blood sugar is the primary driver of nerve damage, and there is strong evidence that tight glycemic control — especially early in the course of diabetes — can slow or even halt the progression of DPN. Newer medication classes, including GLP-1 receptor agonists and SGLT2 inhibitors, have shown promising neuroprotective properties in addition to their glucose-lowering effects, and research in this area is ongoing.
Regular physical activity, healthy weight management, smoking cessation, and limiting alcohol are also important pillars of DPN prevention and management.
Why Seeing a Foot Specialist Matters
Diabetic peripheral neuropathy doesn’t just cause pain — it silently removes the body’s natural warning system for foot injuries. A foot that has lost sensation is vulnerable to wounds that can worsen rapidly and, without proper care, lead to infection, osteomyelitis, or amputation. Regular foot exams by a podiatric specialist are an essential part of comprehensive diabetes care.
Comments
